What We Know So Far About Waning Vaccine Effectiveness - The New York Times
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study - The Lancet
What We Know So Far About Waning Vaccine Effectiveness - The New York Times
Why do Covid boosters offer greater protection against Omicron?
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study - The Lancet Infectious Diseases
Boosters wane but showed protection against hospitalization during omicron, CDC study says - The Washington Post
COVID-19 Vaccine Boosters at VA Long Beach and New Website
What We Know About Getting a Second Booster Shot of COVID-19 Vaccines | The Scientist Magazine®
Why don't COVID-19 vaccines last longer? | World Economic Forum
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England | Nature Medicine
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases
Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR
Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina | NEJM
Boosting with updated COVID-19 mRNA vaccines | Nature Medicine
Covid booster vaccines effective against severe illness from omicron, CDC says
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ
Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years — United States, August 13, 2021–November 19, 2021 | MMWR
COVID-19 BOOSTER VACCINE EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION – in reducing breakthrough, duration of benefit
